FDA approves Zoryve for atopic dermatitis in young children
The recent approval by the FDA for Zoryve (roflumilast) cream 0.05% marks a significant advancement in the treatment of atopic dermatitis in young children. This topical treatment is specifically designed for children aged 2 to 5, providing a much-needed option for parents seeking effective and safe therapies for their children. With Zoryve’s steroid-free formulation, it … Read more